Concepedia

Prognostic Factors and Prognostic Index for Chemonaïve and Gemcitabine-Refractory Patients with Advanced Pancreatic Cancer

Raphaël Maréchal, Anne Demols, Fabien Gay, Viviane de Maertelaere, Marianna Arvanitaki, Alain Hendlisz, Jean‐Luc Van Laethem

Oncology · 2007 · 58 citations · 32 references

DOI

Abstract

Predictive factors could be identified in first- and second-line treatments, although they require prospective validation before they could be used in the design and analysis of future clinical trials.

References

32

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.8K citations

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore, David Goldstein, John Hamm et al. · Journal of Clinical Oncology · 2007 · 3.8K citations

Cancer Statistics, 2002

Ahmedin Jemal, Anish Thomas, Thomas S. Murray et al. · CA A Cancer Journal for Clinicians · 2002 · 2.9K citations · Full text

, , +12

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

Richard Peto, Malcolm C. Pike, P. Armitage et al. · British Journal of Cancer · 1976 · 2.3K citations · Full text

, , +11

Compensated cirrhosis: Natural history and prognostic factors

Pere Ginès, Enrique Quintero, Vicente Arroyo et al. · Hepatology · 1987 · 1.1K citations · Full text

, , +16